Takeda Pharmaceutical Co. Ltd.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. carries a market capitalization of 7.93T, placing it among publicly traded companies globally. Its enterprise value stands at 12.35T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Takeda Pharmaceutical Co. Ltd.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. has 1.58B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.72, and the price-to-book ratio stands at 1.05.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. trades at an EV/EBITDA multiple of 18.33 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 535.20 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 12.35T versus a market cap of 7.93T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. maintains a current ratio of 1.14, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 65.35, indicating elevated leverage, while an interest coverage ratio of 6.43 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. posted a negative return on equity (ROE) of -2.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.10, reflecting losses generated across the asset base. The company generates approximately 97.77M in revenue per employee across its workforce of 47,242.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.19 indicates how many times Takeda Pharmaceutical Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. recorded 32.88B in income tax expense. The company reported a pretax loss of -130.27B and -163.44B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 30, 2026, Takeda Pharmaceutical Co. Ltd.'s stock has gained approximately 25.09% over the past 52 weeks. The 50-day moving average sits at 4,549.70, while the 200-day moving average is 3,971.33.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. generated 4.62T in revenue and converted that into -163.44B in net income, yielding earnings per share of -102.50. EBITDA reached 673.49B, while operating income came in at 481.30B.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. holds 527.58B in cash and equivalents against 4.94T in total debt, resulting in a net debt position of 4.48T. Total book value stands at 7.56T, with working capital of 385.72B providing operational flexibility.

Takeda Pharmaceutical Co. Ltd. produced 826.14B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -339.59B in capital expenditures, free cash flow totaled 486.54B - equivalent to 307.99 per share.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. posted a gross margin of 65.50, reflecting its pricing power and cost economics. The operating margin of 10.42 and net profit margin of -3.54 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Takeda Pharmaceutical Co. Ltd. paid dividends of 105.47 per share. The dividend payout ratio of -102.30 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 6.09, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.56, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Takeda Pharmaceutical Co. Ltd. shareholders.

Takeda Pharmaceutical Co. Ltd.'s most recent stock split took place on March 28, 1988 with a 10:11 split ratio.

As of June 30, 2026, Takeda Pharmaceutical Co. Ltd. has an Altman Z-Score of 1.78, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.